Cargando…

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis

Detalles Bibliográficos
Autores principales:	Colado, Ana, Genoula, Melanie, Cougoule, Céline, Marín Franco, José L., Almejún, María B., Risnik, Denise, Kviatcovsky, Denise, Podaza, Enrique, Elías, Esteban E., Fuentes, Federico, Maridonneau-Parini, Isabelle, Bezares, Fernando R., Fernandez Grecco, Horacio, Cabrejo, María, Jancic, Carolina, Sasiain, María del Carmen, Giordano, Mirta, Gamberale, Romina, Balboa, Luciana, Borge, Mercedes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218455/ https://www.ncbi.nlm.nih.gov/pubmed/30397191 http://dx.doi.org/10.1038/s41408-018-0136-x

Ejemplares similares

Revisiting the role of interleukin-8 in chronic lymphocytic leukemia
por: Risnik, Denise, et al.
Publicado: (2017)

Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia
por: Podaza, Enrique, et al.
Publicado: (2020)

Neglected players: Tumor associated neutrophils involvement in chronic lymphocytic leukemia progression
por: Podaza, Enrique, et al.
Publicado: (2019)

Mycobacterium tuberculosis Multidrug-Resistant Strain M Induces Low IL-8 and Inhibits TNF-α Secretion by Bronchial Epithelial Cells Altering Neutrophil Effector Functions
por: Kviatcovsky, Denise, et al.
Publicado: (2017)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Formation of Foamy Macrophages by Tuberculous Pleural Effusions Is Triggered by the Interleukin-10/Signal Transducer and Activator of Transcription 3 Axis through ACAT Upregulation
por: Genoula, Melanie, et al.
Publicado: (2018)

Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
por: Toenjes, Sean T., et al.
Publicado: (2023)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
por: Li, Ling, et al.
Publicado: (2023)

The C-Type Lectin Receptor DC-SIGN Has an Anti-Inflammatory Role in Human M(IL-4) Macrophages in Response to Mycobacterium tuberculosis
por: Lugo-Villarino, Geanncarlo, et al.
Publicado: (2018)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia
por: Colado, Ana, et al.
Publicado: (2021)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
por: Treon, Steven P., et al.
Publicado: (2020)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
por: Natarajan, Gayathri, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
por: Schutt, Steven D., et al.
Publicado: (2015)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway
por: Zhu, Jin-Feng, et al.
Publicado: (2023)

γδ T Lymphocytes: An Effector Cell in Autoimmunity and Infection
por: Shiromizu, Carolina Maiumi, et al.
Publicado: (2018)

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
por: Guo, Ailin, et al.
Publicado: (2015)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2019)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
por: Rao, Huanan, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Mycobacterium tuberculosis Multidrug Resistant Strain M Induces an Altered Activation of Cytotoxic CD8(+) T Cells
por: Geffner, Laura, et al.
Publicado: (2014)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages
por: Dupont, Maeva, et al.
Publicado: (2020)

Podosomes, But Not the Maturation Status, Determine the Protease-Dependent 3D Migration in Human Dendritic Cells
por: Cougoule, Céline, et al.
Publicado: (2018)

Fatty acid oxidation of alternatively activated macrophages prevents foam cell formation, but Mycobacterium tuberculosis counteracts this process via HIF-1α activation
por: Genoula, Melanie, et al.
Publicado: (2020)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

PB1874: BTK GENE MUTATIONS IN RUSSIAN PATIENTS TREATED WITH IBRUTINIB: AS-PCR VERSUS NGS FOR ALLELIC LOAD ASSESSMENT
por: Likold, E., et al.
Publicado: (2022)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
por: Sarapura Martinez, Valeria J., et al.
Publicado: (2023)

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
por: Hamasy, A, et al.
Publicado: (2017)

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
por: Pal, Dhananjaya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mh6uaoffrec8o7ip4n8s37auk5